N
3.50
-0.14 (-3.85%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | NovaBridge Biosciences | - | - |
AIStockmoo 评分
-0.9
| 分析师共识 | 1.5 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | -0.88 |
|
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. It integrates scientific discovery with strategic planning and project management to move therapies from research toward potential patient use. Its pipeline includes Givastomig, VIS-101, Ragistomig and Uliledlimab. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Ariose Capital Management Ltd | 31 Dec 2025 | 1,363,515 |
| Exome Asset Management Llc | 31 Dec 2025 | 499,587 |
| Aihc Capital Management Ltd | 31 Dec 2025 | 413,979 |
| 52周波幅 | ||
| 中 | 9.00 (157.14%) | |
| 总计 | 1 购买 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 06 Feb 2026 | 9.00 (157.14%) | 购买 | 3.70 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合